Scarica l'app Stockscreener
2.78
1.77%
-0.05
Dopo l'orario di chiusura:
2.78
Protalix BioTherapeutics Inc. Borsa (PLX) Ultime notizie
Retail Trends: Should I invest in Protalix BioTherapeutics Inc before earningsJuly 2025 Selloffs & Reliable Volume Spike Alerts - baoquankhu1.vn
MAK Capital Group (PLX) reports 4,649,599 shares, a 5.8% stake - Stock Titan
Published on: 2026-03-01 19:16:31 - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Protalix BioTherapeutics Reports First Quarter 2025 Financial an - GuruFocus
PLX Should I Buy - Intellectia AI
Protalix BioTherapeutics (NYSE:PLX) Shares Down 0.7%Time to Sell? - MarketBeat
Protalix Biotherapeutics Hits New 52-Week High of $3.19 - Markets Mojo
Is Protalix BioTherapeutics Inc a top pick in the sectorTrade Ideas & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Published on: 2026-02-21 10:08:13 - baoquankhu1.vn
What is the PEG ratio of Protalix BioTherapeutics Inc.Earnings Trend Report & Safe Entry Trade Signal Reports - mfd.ru
Should I invest in Protalix BioTherapeutics Inc. before earnings2025 AllTime Highs & Risk Controlled Stock Pick Alerts - mfd.ru
Swing Trade: Will Protalix BioTherapeutics Inc benefit from rising consumer demandMarket Activity Recap & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Why Protalix BioTherapeutics Inc. stock could be next big winnerEarnings Summary Report & Safe Entry Momentum Stock Tips - mfd.ru
Shorts Report: Will Protalix BioTherapeutics Inc. (DE) stock outperform benchmarks2025 Macro Impact & Daily Risk Controlled Trade Plans - mfd.ru
Will Protalix BioTherapeutics Inc. benefit from rising consumer demandGap Down & Short-Term Trading Alerts - mfd.ru
Will Protalix BioTherapeutics Inc. benefit from government policy2025 Price Momentum & Weekly Momentum Stock Picks - mfd.ru
Protalix Highlights Positive EMA Opinion on Elfabrio Dosing - TipRanks
Protalix BioTherapeutics, Inc. Announces Positive CHMP Opinion for Elfabrio® - TradingView
Why retail investors favor Protalix BioTherapeutics Inc. stockTrade Analysis Report & Risk Adjusted Swing Trade Ideas - mfd.ru
Fabry Disease Market Hits USD 1.7 Billion in 2024, Set for Strong Expansion Across the 7MM Through 2034 | DelveInsight - Barchart.com
RSI Check: Is Protalix BioTherapeutics Inc currently under institutional pressureWeekly Market Summary & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Aug Patterns: Should I invest in Protalix BioTherapeutics Inc before earnings2025 Technical Patterns & Consistent Return Strategy Ideas - baoquankhu1.vn
Protalix Biotherapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
What is Zacks Small Cap’s Forecast for PLX FY2025 Earnings? - Defense World
Protalix BioTherapeutics (NYSE:PLX) Trading Up 6.2%Here's Why - MarketBeat
Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT) - Defense World
Protalix BioTherapeutics (PLX) Price Target Decreased by 12.00% to 11.22 - Nasdaq
PLX: CHMP Delivers Positive Opinion - Research Tree
Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy - MSN
A March Decision That Could Change Protalix BioTherapeutics Outlook - Seeking Alpha
Protalix's New Dosing Regimen Recommended for Approval - Intellectia AI
Protalix (PLX) Surges 14% on Positive EMA Panel Opinion for Elfa - GuruFocus
Protalix rises as EU backs new dosing for Elfabrio (PLX:NYSE) - Seeking Alpha
Protalix (PLX) Gains Positive EMA Opinion for New Elfabrio Dosage - GuruFocus
Protalix Wins EMA Panel Backing for New Elfabrio Dosing - TipRanks
Protalix wins EU panel backing for expanded dosing of Fabry disease drug - Proactive financial news
Protalix BioTherapeutics Announces Positive CHMP Opinion for Elfabrio Dosing Regimen - TradingView
CHMP backs new Elfabrio regimen for Protalix (NYSE: PLX) patients - Stock Titan
Chiesi Global Rare Diseases and Protalix BioTherapeutics - GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU - GlobeNewswire
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU - Yahoo Finance
Market movers: Verizon, Sandisk, Protalix Biotherapeutics, American Express… - Proactive financial news
Is Protalix BioTherapeutics Inc. a strong candidate for buy and holdJuly 2025 Retail & Weekly Return Optimization Alerts - mfd.ru
Aug Summary: Should I invest in Rentokil Initial plc Depositary Receipt before earningsJuly 2025 Movers & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Winners Losers: Can Protalix BioTherapeutics Inc sustain its profitabilityM&A Rumor & Consistent Profit Trading Strategies - baoquankhu1.vn
Can Protalix BioTherapeutics Inc. lead its sector in growthPortfolio Performance Summary & Weekly Breakout Watchlists - bollywoodhelpline.com
Analyst Calls: Is PCG.PRH stock influenced by commodity prices2025 Volatility Report & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Selloffs: What is Protalix BioTherapeutics Inc. s 5 year growth outlookJuly 2025 Earnings & Daily Profit Focused Screening - bollywoodhelpline.com
SQZ Biotechnologies (NYSE:SQZ) vs. Protalix BioTherapeutics (NYSE:PLX) Critical Review - Defense World
Protalix, Secarna in agreement to develop rare kidney disorder therapies - MSN
Why Protalix BioTherapeutics Inc. (DE) stock remains stableJuly 2025 Technicals & Risk Adjusted Swing Trade Ideas - Улправда
Will Protalix BioTherapeutics Inc. (PBDA) stock outperform Dow JonesJuly 2025 Big Picture & Short-Term High Return Strategies - ulpravda.ru
Can Protalix BioTherapeutics Inc. stock hit analyst price targetsJuly 2025 WrapUp & Reliable Intraday Trade Plans - Улправда
Will Protalix BioTherapeutics Inc. stock gain from strong economyStop Loss & Target Return Focused Stock Picks - Улправда
Baozun And 2 Other Promising Penny Stocks - simplywall.st
Is Protalix BioTherapeutics Inc. (DE) stock dividend growth reliableMarket Performance Recap & High Conviction Trade Alerts - Улправда
Is Protalix BioTherapeutics Inc. (PBDA) stock a safe buy pre earningsJuly 2025 Short Interest & Fast Moving Trade Plans - Улправда
Will Protalix BioTherapeutics Inc. (PBDA) stock sustain dividend payoutsPortfolio Value Report & Daily Chart Pattern Signal Reports - Улправда
Is Protalix BioTherapeutics Inc. (PBDA) stock among top earnings playsWeekly Investment Report & Stepwise Trade Signal Implementation - Улправда
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):